- Business Wire•2 months ago
As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin.
- Business Wire•3 months ago
81 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease show reversal of the progression of Parkinson’s disease as measured by globally accepted and validated Unified Parkinson’s Disease Rating Scale .
- Business Wire•5 months ago
Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016.
Living Cell Technologies Limited (LCT.AX)
ASX - ASX Delayed Price. Currency in AUD
|Day's Range||0.09 - 0.09|
|52wk Range||0.04 - 0.11|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-12.86|
|Avg Vol (3m)||1,321,309|
|Dividend & Yield||N/A (N/A)|